SMMT Summit Therapeutics Inc.

Nasdaq summittxinc.com


$ 21.20 $ -0.98 (-4.46 %)    

Friday, 17-Oct-2025 19:39:00 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 20.99
$ 21.43
$ 21.05 x 100
$ 21.60 x 700
$ 20.17 - $ 22.34
$ 15.55 - $ 36.91
4,242,512
na
15.59B
$ 0.34
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 02-24-2025 12-31-2024 10-K
4 10-30-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-01-2024 03-31-2024 10-Q
7 02-20-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-09-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-17-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
20 11-16-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 summit-therapeutics-initiates-global-phase-iii-harmoni-gi3-trial-evaluating-ivonescimab-plus-chemotherapy-in-metastatic-colorectal-cancer

HARMONi-GI3 is the Fourth Global Phase III Study of Ivonescimab and First Global Study beyond NSCLCClinical Trial Site Activati...

 intel-marvell-electronic-arts-are-among-the-top-10-large-cap-gainers-last-week-sep-22---sep-26-are-the-others-in-your-portfolio

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?

 nvidia-high-fives-palantir-rocket-lab--on-this-list-of-10-bagger-legends

Ten stocks in the large-cap Russell 1000 index have achieved at least 1,000% returns since the October 2022 bull market bottom,...

 barclays-initiates-coverage-on-summit-therapeutics-with-underweight-rating-announces-price-target-of-13

Barclays analyst Etzer Darout initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Underweight rating and announce...

 hc-wainwright--co-reiterates-buy-on-summit-therapeutics-maintains-50-price-target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $50...

 jim-cramer-ring-the-register-on-this-real-estate-meme-stock

On CNBC's "Mad Money Lightning Round," Jim Cramer recommended ditching Opendoor: "We don't want to be in a ...

 synopsys-chewy-and-the-trade-desk-are-among-top-10-large-cap-losers-last-week-sep-8--sep-12-are-the-others-in-your-portfolio

Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biote...

 cantor-fitzgerald-reiterates-overweight-on-summit-therapeuticsto-overweight

Cantor Fitzgerald analyst Eric Schmidt reiterates Summit Therapeutics (NASDAQ:SMMT) from Overweight to Overweight.

 summit-therapeutics-lung-cancer-drug-under-dark-clouds-as-keytruda-challenger-shows-regional-data-differences

Summit's ivonescimab showed improved survival trends in NSCLC patients with favorable safety, though some results missed st...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION